Key Takeaway: Nurix is committed to developing innovative therapies through its multi-modal portfolio. The company focuses on translating scientific insights into effective treatments for cancer and autoimmune diseases. Their approach includes the use of protein degradation resources to enhance therapeutic outcomes.
Price reaction · baseline $8.32 (2023-09-27 close) · hit pre-market · clean, no other NRIX news in the window
day 0 close · peak
-2.2%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix is focused on translating scientific insights into therapies.
The company is advancing a multi-modal portfolio.
They aim to combat cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-2127?
NX-2127 is a novel degrader targeting BTK and IKZF1/3 developed by Nurix.
What diseases does NX-2127 aim to treat?
NX-2127 is designed to combat cancer and autoimmune diseases.
What is Nurix's focus?
Nurix focuses on translating scientific insights into breakthrough therapies.
What resources does Nurix provide?
Nurix offers protein degradation resources to advance their therapeutic portfolio.